Page last updated: 2024-11-02

pilsicainide and Heart Failure

pilsicainide has been researched along with Heart Failure in 2 studies

pilsicainide: structure given in first source
pilsicainide : A secondary carboxamide resulting from the formal condensation of the amino group of 2,6-dimethylaniline with the carboxy group of (tetrahydro-1H-pyrrolizin-7a(5H)-yl)acetic acid. It is a sodium channel blocker which is used as an antiarrhythmic drug for the management of atrial tachyarrhythmias in Japan.

Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.

Research Excerpts

ExcerptRelevanceReference
"Pilsicainide (75 mg/day) was administered to reduce the LVOTO."1.56Development of Pulmonary Edema Despite Negative Fluid Balance with Diuretics in a Patient with Heart Failure and Sigmoid Septum. ( Kamono, M; Komatsu, R; Miyazaki, K; Onuma, Y, 2020)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Miyazaki, K1
Onuma, Y1
Komatsu, R1
Kamono, M1
Nattel, S1

Other Studies

2 other studies available for pilsicainide and Heart Failure

ArticleYear
Development of Pulmonary Edema Despite Negative Fluid Balance with Diuretics in a Patient with Heart Failure and Sigmoid Septum.
    The Tokai journal of experimental and clinical medicine, 2020, Apr-20, Volume: 45, Issue:1

    Topics: Aged, 80 and over; Diuretics; Furosemide; Heart Failure; Humans; Lidocaine; Male; Pulmonary Edema; V

2020
Effects of ionic remodeling on cardiac antiarrhythmic drug actions.
    Journal of cardiovascular pharmacology, 2001, Volume: 38, Issue:6

    Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Down-Regulation; Electric C

2001